Susceptibility of Streptococcus Pneumoniae to Penicillin, Azithromycin and Telithromycin (PROTEKT 1999-2003)
Overview
Pharmacology
Authors
Affiliations
Isolates of Streptococcus pneumoniae collected over the first 4 years of the PROTEKT study were tested for susceptibility to penicillin, azithromycin and telithromycin. A total of 20,750 isolates were collected from 39 countries. Penicillin non-susceptibility rates were stable over the study period; overall, 21.8% of isolates were resistant. Azithromycin resistance increased from 31.0% in Year 1 to 36.3% in Year 4. Resistance rates for penicillin and azithromycin varied between countries and were highest in France, Spain, South Africa, USA and the Far East. Multidrug resistance in S. pneumoniae did not change significantly over the 4 years, with an overall rate of 38.6%. Telithromycin retained good activity against S. pneumoniae (0.1% of isolates resistant), including multidrug-resistant isolates.
Severe problem of macrolides resistance to common pathogens in China.
Li J, Liu L, Zhang H, Guo J, Wei X, Xue M Front Cell Infect Microbiol. 2023; 13:1181633.
PMID: 37637457 PMC: 10448830. DOI: 10.3389/fcimb.2023.1181633.
Hart J, Samikwa L, Meleke H, Burr S, Cornick J, Kalua K Lancet Microbe. 2022; 3(2):e142-e150.
PMID: 35156069 PMC: 8819720. DOI: 10.1016/S2666-5247(21)00279-2.
Yayan J Drug Des Devel Ther. 2014; 8:1733-43.
PMID: 25336917 PMC: 4199971. DOI: 10.2147/DDDT.S71349.
Bos J, Beishuizen S, Madeira G, Gomonda E, Cossa E, Macome A BMC Res Notes. 2014; 7:110.
PMID: 24568650 PMC: 3939630. DOI: 10.1186/1756-0500-7-110.
Kim H, Kim S, Chang H, Lee J, Peck K Infect Chemother. 2014; 45(4):394-405.
PMID: 24475353 PMC: 3902813. DOI: 10.3947/ic.2013.45.4.394.